PlantPharma

See the full text of this article here.

A telephone survey of United States consumers’ views on tobacco biopharming indicates widespread support for developing the technology when it generates a socially beneficial application.

Perceptions of risks associated with the technology, however, are split: Most respondents either hold concerns in every risk area presented or in none of them. Willingness to purchase a bio-tobacco-based medicine is bimodal as well.

These polarized perceptions point to the challenges faced by policy makers who attempt to implement regulatory oversight of biopharming by balancing the broad-based concerns of the public against the potentially significant benefits of the technology.